Denosumab and incidence of type 2 diabetes among adults with osteoporosis: population based cohort study
Main finding · Incident type 2 diabetesResult — go to the resultHazard ratio 0.68 95% CI 0.52–0.89Authors' conclusion
In this population based study, denosumab use was associated with a lower risk of incident type 2 diabetes compared with oral bisphosphonate use in adults with osteoporosis.
Study context
- Population
- Adults aged 45 years or older using denosumab or an oral bisphosphonate for osteoporosis; IQVIA Medical Research Data primary care database, UK, 1995–2021mean follow-up 2.2 years
- Participants
- 4,301 vs 21,038
- Exposure
- Denosumab vs oral bisphosphonates
- Denosumabn = 4,301
- Oral bisphosphonaten = 21,038reference
- Outcome
- Incident type 2 diabetes, as defined by diagnostic codes
Methodological detailstarget trial emulation, emulation of a randomized target trial, electronic health records, propensity-score matched, as treated approach, Cox proportional hazards models
- Target trial emulation
- Emulation of a randomized target trial
- Electronic health records
- Propensity-score matched
- As treated approach
- Cox proportional hazards models
Main finding
Incident type 2 diabetes
Hazard ratio
0.68
95% CI 0.52–0.89
By group
Denosumabvs Oral bisphosphonate
HR 0.68 (95% CI 0.52–0.89)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (CI) | |
|---|---|---|
| Incident type 2 diabetes in participants with prediabetes (subgroup) | 0.54 (0.35–0.82) | |
| Incident type 2 diabetes in participants with BMI ≥30 (subgroup) | 0.65 (0.40–1.06) | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Denosumab and incidence of type 2 diabetes among adults with osteoporosis: population based cohort study. BMJ. Published 18 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →